Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

683 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: lenz hj. Clin Cancer Res. 2006 Mar 1;12(5):1556-63. doi: 10.1158/1078-0432.CCR-05-2074. Clin Cancer Res. 2006. PMID: 16533781 Clinical Trial.
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Yen Y, et al. Among authors: lenz hj. Cancer Chemother Pharmacol. 2002 Nov;50(5):353-9. doi: 10.1007/s00280-002-0492-9. Epub 2002 Sep 12. Cancer Chemother Pharmacol. 2002. PMID: 12439592 Clinical Trial.
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH. Juhasz A, et al. Among authors: lenz hj. J Clin Lab Anal. 2003;17(5):184-94. doi: 10.1002/jcla.10091. J Clin Lab Anal. 2003. PMID: 12938148 Free PMC article. Clinical Trial.
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P. Doroshow JH, et al. Among authors: lenz hj. Semin Oncol. 2003 Aug;30(4 Suppl 15):14-9. doi: 10.1016/s0093-7754(03)00400-7. Semin Oncol. 2003. PMID: 14523790 Clinical Trial.
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium. Lara PN Jr, et al. Among authors: lenz hj. Clin Cancer Res. 2003 Oct 15;9(13):4772-81. Clin Cancer Res. 2003. PMID: 14581348 Clinical Trial.
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: lenz hj. Anticancer Drugs. 2005 Mar;16(3):317-21. doi: 10.1097/00001813-200503000-00011. Anticancer Drugs. 2005. PMID: 15711184 Clinical Trial.
683 results